Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX EBITDA Margin
EBITDA as a percentage of revenue.
Janux Therapeutics, Inc.NASDAQ: JANX
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin at -640.0%
EBITDA Margin was -640.0% in Q1 FY2026. On a trailing-twelve-month basis it was -520.3%, up 290.5 pp year over year. Over 3 fiscal years it narrowed by 393.5 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 11 analysts of -331.3% for the fiscal year ending Dec 2026, up from -1116.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -640.0%-241.2 pp QoQ
- Last fiscal yearDec 2025
- -1116.0%-483.8 pp YoY
- LTMMar 2026
- -520.3%+290.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -483.8 pp | +784.7 pp | +1268.5 pp |
| 3 years | -393.5 pp | -1940.1 pp | -1546.6 pp |
| 5 years | +972.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1116.0%
- Year-over-year change
- -483.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1116.0% | -483.8pp |
| FY2024 | 2024-12-31 | -632.2% | +64.8pp |
| FY2023 | 2023-12-31 | -697.0% | +25.5pp |
| FY2022 | 2022-12-31 | -722.5% | +172.8pp |
| FY2021 | 2021-12-31 | -895.2% | — |
EBITDA Margin vs competitors
How JANX compares with its peers on the latest reported figures
- JANX's LTM Mar 2026 EBITDA Margin of -520.3% is the 5th highest of the 8 companies compared; the peer median is -162.2%.
- Its year-over-year change of +290.5 pp is the highest of 8, against a peer median of -191.7 pp.
- Over three fiscal years its change of -393.5 pp compares with a peer median of +22.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 7.3% | +27.5 pp | +333.4 pp | |
| LTM Mar 2026 | -32.2% | -1.2 pp | +32.0 pp | |
| LTM Mar 2026 | -106.5% | +169.1 pp | +12.9 pp | |
| LTM Mar 2026 | -162.2% | -191.7 pp | +161.5 pp | |
| LTM Mar 2026 | -520.3% | +290.5 pp | -393.5 pp | |
| LTM Mar 2026 | -542.7% | -539.6 pp | -412.4 pp | |
| FY2025 | -3017.4% | -1343.3 pp | — | |
| LTM Sep 2026 | -272652.7% | -264146.9 pp | -12607.1 pp | |
| FY2025 | — | — | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding JANX) | -162.2% | -191.7 pp | +22.5 pp | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.64M | 8.61M | 8.08M | 10.59M | 10M |
| Cost of Revenue | 26.24M | 841K | 1.96M | 2.06M | 2.03M |
| Gross Profit | (22.6M) | 7.77M | 6.13M | 8.53M | 7.97M |
| Gross Margin | -621.4% | 90.2% | 75.8% | 80.5% | 79.7% |
| Research & Development | 26.24M | 53.44M | 54.92M | 68.39M | 125.9M |
| Selling, General & Admin | 10.33M | 22.26M | 26.14M | 41.05M | 41.77M |
| Operating Expenses | 10.33M | 74.86M | 79.11M | 107.38M | 165.64M |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| EBITDA | (32.56M) | (62.22M) | (56.34M) | (66.93M) | (111.6M) |
| EBITDA Margin | -895.2% | -722.5% | -697.0% | -632.2% | -1116.0% |
| Operating Income | (32.93M) | (67.09M) | (72.98M) | (98.85M) | (157.67M) |
| Operating Margin | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| Interest Income | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Income Before Tax | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Pre-Tax Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Net Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| EPS (Basic) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| EPS (Diluted) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| Weighted Avg Shares | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
| Weighted Avg Shares (Diluted) | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.